Horizon Pharma (NASDAQ:HZNP) has been assigned a $17.00 price objective by investment analysts at Cantor Fitzgerald in a report issued on Monday, January 8th. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 13.41% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the stock. Jefferies Group reissued a “buy” rating and issued a $16.00 price target on shares of Horizon Pharma in a research note on Thursday, October 5th. Goldman Sachs Group started coverage on Horizon Pharma in a report on Thursday, September 28th. They issued a “buy” rating and a $16.00 price objective on the stock. ValuEngine lowered Horizon Pharma from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. BidaskClub upgraded Horizon Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Finally, UBS Group set a $20.00 price target on Horizon Pharma and gave the stock a “buy” rating in a report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $19.25.
Shares of Horizon Pharma (NASDAQ:HZNP) traded up $0.37 during trading hours on Monday, reaching $14.99. 1,968,100 shares of the company traded hands, compared to its average volume of 1,979,418. Horizon Pharma has a one year low of $9.45 and a one year high of $17.69. The company has a current ratio of 1.64, a quick ratio of 1.52 and a debt-to-equity ratio of 1.89. The firm has a market cap of $2,530.00, a P/E ratio of -4.93, a PEG ratio of 0.68 and a beta of 1.30.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The business had revenue of $271.60 million for the quarter, compared to analysts’ expectations of $259.74 million. During the same quarter last year, the company earned $0.70 EPS. The business’s revenue was up 30.1% on a year-over-year basis. research analysts anticipate that Horizon Pharma will post 0.72 EPS for the current year.
Institutional investors have recently made changes to their positions in the company. Sheaff Brock Investment Advisors LLC lifted its stake in Horizon Pharma by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 500 shares during the last quarter. Prudential Financial Inc. lifted its stake in Horizon Pharma by 5.0% in the second quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 830 shares during the last quarter. Amalgamated Bank lifted its stake in Horizon Pharma by 4.8% in the second quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 943 shares during the last quarter. Bank of Montreal Can lifted its stake in Horizon Pharma by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 1,378 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Horizon Pharma by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock valued at $1,495,000 after buying an additional 1,379 shares during the last quarter. 86.58% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/18/cantor-fitzgerald-analysts-give-horizon-pharma-hznp-a-17-00-price-target.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.